Eric W. Thomas

Array ( [id] => 9792245 [patent_doc_number] => 20150004190 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-01 [patent_title] => 'VACCINE COMPOSITIONS FOR HIV PREVENTION AND TREATMENT' [patent_app_type] => utility [patent_app_number] => 14/374121 [patent_app_country] => US [patent_app_date] => 2013-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 18895 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14374121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11813855 [patent_doc_number] => 09717788 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-01 [patent_title] => 'Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant' [patent_app_type] => utility [patent_app_number] => 13/744867 [patent_app_country] => US [patent_app_date] => 2013-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 23487 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13744867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10114655 [patent_doc_number] => 09149519 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-10-06 [patent_title] => 'Chimeric human immunodeficiency virus type 1 (HIV-1) with enhanced dendritic cell and macrophage tropism comprising the simian immunodeficiency virus (SIV) minimal Vpx packaging domain' [patent_app_type] => utility [patent_app_number] => 13/743877 [patent_app_country] => US [patent_app_date] => 2013-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 24 [patent_no_of_words] => 29023 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13743877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10967011 [patent_doc_number] => 20140370043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-18 [patent_title] => 'VESICULAR STOMATITIS VIRUS FOR PRIME BOOST VACCINE' [patent_app_type] => utility [patent_app_number] => 14/368102 [patent_app_country] => US [patent_app_date] => 2012-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 17230 [patent_no_of_claims] => 77 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14368102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11921569 [patent_doc_number] => 09789130 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-17 [patent_title] => 'Method for blocking HIV entry into dendritic cells by inhibiting sialoadhesin-sialyllactose binding interactions with gangliosides' [patent_app_type] => utility [patent_app_number] => 14/366839 [patent_app_country] => US [patent_app_date] => 2012-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 15 [patent_no_of_words] => 34259 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14366839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11277073 [patent_doc_number] => 09493549 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-15 [patent_title] => 'Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth' [patent_app_type] => utility [patent_app_number] => 13/714398 [patent_app_country] => US [patent_app_date] => 2012-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 43 [patent_no_of_words] => 20384 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13714398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9331166 [patent_doc_number] => 20140057948 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-27 [patent_title] => 'VIF AS A TARGET FOR HIV INHIBITION' [patent_app_type] => utility [patent_app_number] => 13/710901 [patent_app_country] => US [patent_app_date] => 2012-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 10862 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13710901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11722382 [patent_doc_number] => 09695230 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-07-04 [patent_title] => 'Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein' [patent_app_type] => utility [patent_app_number] => 14/363740 [patent_app_country] => US [patent_app_date] => 2012-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 87 [patent_figures_cnt] => 88 [patent_no_of_words] => 76001 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14363740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8865620 [patent_doc_number] => 20130149323 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-13 [patent_title] => 'MUTATED LENTIVIRAL ENV PROTEINS AND THEIR USE AS DRUGS' [patent_app_type] => utility [patent_app_number] => 13/707885 [patent_app_country] => US [patent_app_date] => 2012-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 26938 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13707885 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11684107 [patent_doc_number] => 09682137 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-06-20 [patent_title] => 'Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties' [patent_app_type] => utility [patent_app_number] => 14/363095 [patent_app_country] => US [patent_app_date] => 2012-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 6 [patent_no_of_words] => 26252 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14363095 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12469527 [patent_doc_number] => 09988424 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-05 [patent_title] => Immunogens comprising human immunodeficiency virus V1/V2 polypeptides [patent_app_type] => utility [patent_app_number] => 14/363131 [patent_app_country] => US [patent_app_date] => 2012-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 173 [patent_figures_cnt] => 61 [patent_no_of_words] => 44463 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14363131 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10953842 [patent_doc_number] => 20140356863 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-04 [patent_title] => 'METHODS FOR DETERMINING THE SUSCEPTIBILITY OF A VIRUS TO AN ATTACHMENT INHIBITOR' [patent_app_type] => utility [patent_app_number] => 14/365786 [patent_app_country] => US [patent_app_date] => 2012-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 6781 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14365786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9771349 [patent_doc_number] => 20140295012 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-02 [patent_title] => 'LATENT HUMAN IMMUNODEFICIENCY VIRUS REACTIVATION' [patent_app_type] => utility [patent_app_number] => 14/358542 [patent_app_country] => US [patent_app_date] => 2012-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 17888 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14358542 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9042326 [patent_doc_number] => 20130244964 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-19 [patent_title] => 'NOVEL HIV-1 REVERSE TRANSCRIPTASE CODON DELETION AND ITS USE IN THE MANAGEMENT AND TREATMENT OF HIV INFECTIONS' [patent_app_type] => utility [patent_app_number] => 13/672761 [patent_app_country] => US [patent_app_date] => 2012-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 20731 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13672761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8891132 [patent_doc_number] => 20130164316 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-27 [patent_title] => 'GENETIC SIGNATURES IN HIV-1 SUBTYPE C ENVELOPE GLYCOPROTEINS' [patent_app_type] => utility [patent_app_number] => 13/671490 [patent_app_country] => US [patent_app_date] => 2012-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 10939 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13671490 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10912172 [patent_doc_number] => 20140315188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-23 [patent_title] => 'ASSESSMENT OF PML RISK AND METHODS BASED THEREON' [patent_app_type] => utility [patent_app_number] => 14/351782 [patent_app_country] => US [patent_app_date] => 2012-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 69374 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14351782 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10077347 [patent_doc_number] => 09115189 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-08-25 [patent_title] => 'Monoclonal antibodies to human immunodeficiency virus and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/647735 [patent_app_country] => US [patent_app_date] => 2012-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 18 [patent_no_of_words] => 13935 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13647735 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8648834 [patent_doc_number] => 20130034564 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-02-07 [patent_title] => 'ANTI-RSV G PROTEIN ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/626852 [patent_app_country] => US [patent_app_date] => 2012-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 10808 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13626852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8989245 [patent_doc_number] => 20130216526 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-22 [patent_title] => 'METHODS FOR REDUCING VIRAL LOAD IN HIV-1 INFECTED PATIENTS' [patent_app_type] => utility [patent_app_number] => 13/621590 [patent_app_country] => US [patent_app_date] => 2012-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 56192 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13621590 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8821540 [patent_doc_number] => 20130122585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-16 [patent_title] => 'SYNTHETIC GAGPOL GENES AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 13/615587 [patent_app_country] => US [patent_app_date] => 2012-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 15183 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13615587 [rel_patent_id] =>[rel_patent_doc_number] =>)